Dr. Hartman is a highly trained medical oncologist with 15 years of industry experience in product development with expertise in the clinical development and commercialization of molecular diagnostics in cancer screening and oncology. With an interest in innovative technology platforms to improve patient outcomes and health care, Dr. Hartman has played a pivotal role in the development and commercialization of several molecular diagnostic tests in oncology. This includes leading the design and completion of several large scale clinical trials in early cancer detection and hereditary cancer screening. Her interest in innovative technology ultimately led her to co-found Adela to develop a best-in-class liquid biopsy test for early cancer detection and minimal residual disease detection that avoids the limitations of standard liquid biopsy approaches.
Multi-Cancer Screening Using Adela’s Methylome Profiling Platform
cfMeDIP-seq is a next-generation methylation technology being developed for applications across the cancer care continuum. Technical advantages enable high sensitivity for cancer detection, tissue of origin, histologic subtyping , and identification of underlying biology through distinct patterns of methylation across the cancer methylome.
Early cancer detection technologies have huge potentials to change disease outcome and patient management, yet most of these technologies are still in development. This session discusses latest technological and clinical advancements, clinical limitations and challenges to overcome, and the potential for future applications using the various types of early detection biomarkers.